LCCC 1025: A phase II study evaluating the mTOR inhibitor everolimus with trastuzumab and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
Carey K. Anders
No relevant relationships to disclose
Allison Mary Deal
No relevant relationships to disclose
Elizabeth Claire Dees
Research Funding - GlaxoSmithKline; Millennium; Novartis; Roche/Genentech
William Johnson Irvin
No relevant relationships to disclose
Hyman Bernard Muss
No relevant relationships to disclose
Jeanne Noe
Stock Ownership - Novartis
Olga Karginova
No relevant relationships to disclose
Barbara Adamo
No relevant relationships to disclose
Aleix Prat
No relevant relationships to disclose
Lisa A. Carey
No relevant relationships to disclose